Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax: 2013-2024

Historic Profit After Tax for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$269.9 million.

  • Viridian Therapeutics, Inc.\DE's Profit After Tax rose 54.88% to -$34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.0 million, marking a year-over-year decrease of 17.46%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Profit After Tax stood at -$269.9 million for FY2024, which was down 13.55% from -$237.7 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Profit After Tax peaked at -$79.4 million during FY2021, and registered a low of -$269.9 million during FY2024.
  • Its 3-year average for Profit After Tax is -$212.5 million, with a median of -$237.7 million in 2023.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Profit After Tax crashed by 164.41% in 2020 and then increased by 28.27% in 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Profit After Tax (Yearly) stood at -$110.7 million in 2020, then rose by 28.27% to -$79.4 million in 2021, then crashed by 63.54% to -$129.9 million in 2022, then crashed by 83.05% to -$237.7 million in 2023, then dropped by 13.55% to -$269.9 million in 2024.